• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Septerna Inc.

    3/27/25 8:51:02 AM ET
    $SEPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SEPN alert in real time by email
    S-8 1 d943795ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 27, 2025

    Registration No. 333-   

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SEPTERNA, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   84-3891440

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    Septerna, Inc.

    250 East Grand Avenue

    South San Francisco, California 94080

    (650) 338-3533

    (Address, including zip code and telephone number, including area code, of registrant’s principal executive offices)

    Septerna, Inc. 2024 Stock Option and Incentive Plan

    (Full title of the plans)

    Jeffrey Finer, M.D., Ph.D.

    President and Chief Executive Officer

    Septerna, Inc.

    250 East Grand Avenue

    South San Francisco, California 94080

    (650) 338-3533

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Mitchell S. Bloom

    Deepa M. Rich

    Adam V. Johnson

    Goodwin Procter LLP

    601 Marshall Street

    Redwood City, California 94063

    (650) 752-3100

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed for the purposes of registering an additional 2,221,125 shares of common stock, par value $0.001 per share (“Common Stock”), of Septerna, Inc. (the “Registrant”) to be issued under the Registrant’s 2024 Stock Option and Incentive Plan (the “2024 Plan”).

    The number of shares of Common Stock reserved and available for issuance under the 2024 Plan is subject to an automatic annual increase on each January 1 by an amount equal to the lesser of: (i) five percent (5%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, or (ii) such number of shares of Common Stock as determined by the Administrator (as defined in the 2024 Plan). Accordingly, on January 1, 2025, the number of shares of Common Stock reserved and available for issuance under the 2024 Plan increased by 2,221,125 (the “Additional Shares”). This Registration Statement registers the Additional Shares. The Additional Shares are of the same class as other securities relating to the 2024 Plan for which the Registrant’s Registration Statement on Form S-8 (File No. 333-282837) filed with the Securities and Exchange Commission (the “Commission”) on October 25, 2024 is effective (the “Prior Registration Statement”).

    Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statement, except for “Item 8. Exhibits”, are hereby incorporated by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Prior Registration Statement is presented herein.


    Part II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 8. Exhibits.

    EXHIBIT INDEX

     

    Exhibit No.   

    Description

     4.1    Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on October 28, 2024 (File No. 001-42382)). 
     4.2    Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on October 28, 2024 (File No. 001-42382)). 
     4.3    Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-1, as amended, filed with the Commission on October 21, 2024 (File No. 333-282469)). 
     4.4†    Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated as of June 28, 2023 (incorporated by reference to Exhibit 4.1 to the Registrant’s Registration Statement on Form S-1, as amended, filed with the Commission on October 2, 2024 (File No. 333-282469)). 
     5.1*    Opinion of Goodwin Procter LLP.
    23.1*    Consent of Independent Registered Public Accounting Firm.
    23.2*    Consent of Goodwin Procter LLP (included in Exhibit 5.1).
    24.1*    Power of Attorney (included on signature page).
    99.1    Septerna, Inc. 2024 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Registrant’s Registration Statement on Form S-1, as amended, filed with the Commission on October 21, 2024 (File No. 333-282469)). 
    107*    Filing Fee Table

     

    *

    Filed herewith.

    †

    Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted attachment to the Commission on a confidential basis upon request.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, California, on this 27th day of March, 2025.

     

    SEPTERNA, INC.
    By:   /s/ Jeffrey Finer, M.D., Ph.D.
      Name:   Jeffrey Finer, M.D., Ph.D.
      Title: President, Chief Executive Officer and Director

    POWER OF ATTORNEY AND SIGNATURES

    Each individual whose signature appears below hereby constitutes and appoints each of Jeffrey Finer, M.D., Ph.D. and Gil Labrucherie, CFA, J.D. as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.


    Name

      

    Title

     

    Date

    /s/ Jeffrey Finer, M.D., Ph.D.

    Jeffrey Finer, M.D., Ph.D.

      

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

      March 27, 2025

    /s/ Gil Labrucherie, CFA, J.D.

    Gil Labrucherie, CFA, J.D.

      

    Chief Financial Officer

    (Principal Financial Officer and

    Principal Accounting Officer)

      March 27, 2025

    /s/ Jeffrey Tong, Ph.D.

    Jeffrey Tong, Ph.D.

      

    Chairman and Director

      March 27, 2025

    /s/ Abraham Bassan, M.S.

    Abraham Bassan, M.S.

      

    Director

      March 27, 2025

    /s/ Bernard Coulie, M.D., Ph.D., M.B.A.

    Bernard Coulie, M.D., Ph.D., M.B.A.

      

    Director

      March 27, 2025

    /s/ Alan Ezekowitz, M.D., D.Phil.

    Alan Ezekowitz, M.D., D.Phil.

      

    Director

      March 27, 2025

    /s/ Shalini Sharp, M.B.A.

    Shalini Sharp, M.B.A.

      

    Director

      March 27, 2025

    /s/ Jake Simson, Ph.D.

    Jake Simson, Ph.D.

      

    Director

      March 27, 2025
    Get the next $SEPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SEPN

    DatePrice TargetRatingAnalyst
    2/18/2025$14.00Overweight → Equal Weight
    Wells Fargo
    11/19/2024$38.00Overweight
    Analyst
    11/19/2024Buy
    TD Cowen
    11/19/2024$43.00Overweight
    Wells Fargo
    11/19/2024$50.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $SEPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

      Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later This Year Phase 1 Trial for SEP-631, MRGPRX2 NAM Program for Mast Cell Diseases, Expected to Initiate in 2025 Well-Capitalized with $420.8M Balance Sheet as of YE 2024 to Support Operating Runway into Early 2028 SOUTH SAN FRANCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today provided a corporate overview complete with upcoming milestones and reported fourth quarter and full year 2024 financial results. "Our Native Comp

      3/27/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna to Present at TD Cowen 45th Annual Health Care Conference

      SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 10:30 a.m. ET in Boston. About SepternaSepterna, Inc. is a biotechnology company pioneering a new era of GPCR drug discovery powered by its proprietary Native Complex Platform™. Its industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development

      2/26/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

      Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-786 is an oral small molecule agonist of the parathyroid hormone 1 receptor (PTH1R) being developed for the treatment of hypoparathyroidism.

      2/18/25 8:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Septerna Inc.

      SC 13D - Septerna, Inc. (0001984086) (Subject)

      11/4/24 4:39:38 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Septerna Inc.

      SC 13G - Septerna, Inc. (0001984086) (Subject)

      11/4/24 4:15:38 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Septerna Inc.

      SC 13G - Septerna, Inc. (0001984086) (Subject)

      11/1/24 4:27:45 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/10/25 4:18:19 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/6/25 9:02:51 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO and President Finer Jeffrey bought $96,961 worth of shares (17,000 units at $5.70), increasing direct ownership by 2% to 771,907 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      2/27/25 6:53:01 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SEPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CEO and President Finer Jeffrey exercised 55,000 shares at a strike of $2.76, increasing direct ownership by 7% to 826,907 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      4/4/25 4:13:25 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $92,270 worth of shares (13,319 units at $6.93), increasing direct ownership by 13% to 117,420 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/10/25 4:18:19 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ezekowitz Alan bought $515,934 worth of shares (86,681 units at $5.95), increasing direct ownership by 498% to 104,101 units (SEC Form 4)

      4 - Septerna, Inc. (0001984086) (Issuer)

      3/6/25 9:02:51 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Septerna downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Septerna from Overweight to Equal Weight and set a new price target of $14.00

      2/18/25 8:55:10 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Analyst initiated coverage on Septerna with a new price target

      Analyst initiated coverage of Septerna with a rating of Overweight and set a new price target of $38.00

      11/19/24 7:39:27 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Septerna

      TD Cowen initiated coverage of Septerna with a rating of Buy

      11/19/24 7:39:11 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Septerna Inc.

      DEFA14A - Septerna, Inc. (0001984086) (Filer)

      4/29/25 4:08:35 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Septerna Inc.

      DEF 14A - Septerna, Inc. (0001984086) (Filer)

      4/29/25 4:05:26 PM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Septerna Inc.

      S-8 - Septerna, Inc. (0001984086) (Filer)

      3/27/25 8:51:02 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SEPN
    Leadership Updates

    Live Leadership Updates

    See more
    • Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

      SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotech company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Gil Labrucherie, CFA, J.D., as Chief Financial Officer. Mr. Labrucherie is a seasoned biopharma executive with more than 25 years of senior leadership experience in finance and legal roles for public biopharmaceutical and technology companies. "We are excited to welcome Gil to the team," said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. "His extensive expertise leading public company finance and capital strategy will be ins

      1/6/25 7:00:00 AM ET
      $SEPN
      Biotechnology: Pharmaceutical Preparations
      Health Care